|
Vaccine Detail
NA17.A2 Peptide Vaccine |
Vaccine Information |
- Vaccine Name: NA17.A2 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007093
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MAGEA3
gene engineering:
- MLANA
gene engineering:
- gp100 (PMEL)
gene engineering:
- Preparation: The vaccine included NA17.A2 clinical grade peptide or NA17.A2 combined with MAGE-3.A1 emulsified in Montanide ISA (Parmiani et al., 2014).
- Description: This is for Melanoma Cancer(NCT01307618). A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas. (NCIT_C2680; Trakatelli et al., 2006)
|
Host Response |
|
References |
NCIT_C2680: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2680]
NCT01307618: [https://clinicaltrials.gov/ct2/show/NCT01307618?term=NA17.A2&rank=2]
Parmiani et al., 2014: Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C. A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology. 2014; 3(11); e963406. [PubMed: 25941591].
Trakatelli et al., 2006: Trakatelli M, Toungouz M, Blocklet D, Dodoo Y, Gordower L, Laporte M, Vereecken P, Sales F, Mortier L, Mazouz N, Lambermont M, Goldman S, Coulie P, Goldman M, Velu T. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer immunology, immunotherapy : CII. 2006; 55(4); 469-474. [PubMed: 16133111].
|
|